skip to main content

Giant Cell Arteritis — UKMLA MCQ

Instant feedback + full explanation. One question, done properly.

HardRheumatologyGiant Cell ArteritisUKMLAMRCGP AKTPARAMRCEM SBAMRCP Part 1

An adult with wild-type ATTR cardiomyopathy is clinically suitable for either tafamidis or acoramidis. After discussing administration and adverse effects, neither has a clinical advantage for this patient. What does current NICE guidance require?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Choose the least expensive suitable treatment after shared discussion

The best answer is “Choose the least expensive suitable treatment after shared discussion”. TA1121 makes acoramidis an option for wild-type or hereditary ATTR cardiomyopathy and addresses choice when more than one suitable treatment is available. After discussing the advantages and disadvantages with the patient, NICE says to use the least expensive option, taking administration costs, dosage, price per dose and commercial arrangements into account. It does not establish a clinical preference based on appraisal date or wild-type disease, and it does not recommend combining acoramidis with tafamidis.

Reference: NICE TA1121, Acoramidis for transthyretin amyloidosis with cardiomyopathy: https://www.nice.org.uk/guidance/ta1121/chapter/1-Recommendations